NCM Capital Management’s AbbVie ABBV Stock Holding History

NCM Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Buy	7,769 +250	+3%	+$53.8K	0.6%	44
2026 Q1	$1.64M	Hold	7,519	–	–	0.59%	41
2025 Q4	$1.72M	Buy	7,519 +1	+0%	+$228	0.64%	34
2025 Q3	$1.74M	Sell	7,518 -180	-2%	-$36.7K	0.68%	32
2025 Q2	$1.43M	Hold	7,698	–	–	0.59%	39
2025 Q1	$1.61M	Hold	7,698	–	–	0.73%	30
2024 Q4	$1.37M	Hold	7,698	–	–	0.62%	35
2024 Q3	$1.52M	Hold	7,698	–	–	0.73%	29
2024 Q2	$1.32M	Hold	7,698	–	–	0.69%	34
2024 Q1	$1.4M	Sell	7,698 -50	-0.6%	-$8.62K	0.79%	28
2023 Q4	$1.2M	Sell	7,748 -54	-0.7%	-$7.87K	0.73%	35
2023 Q3	$1.16M	Sell	7,802 -50	-0.6%	-$7.34K	0.83%	27
2023 Q2	$1.06M	Sell	7,852 -45	-0.6%	-$6.6K	0.74%	35
2023 Q1	$1.26M	Buy	7,897 +4	+0.1%	+$612	0.94%	26
2022 Q4	$1.28M	Buy	7,893 +4	+0.1%	+$613	0.84%	34
2022 Q3	$1.06M	Sell	7,889 -16	-0.2%	-$2.3K	0.8%	36
2022 Q2	$1.21M	Sell	7,905 -96	-1%	-$14.7K	0.85%	38
2022 Q1	$1.3M	Buy	8,001 +35	+0.4%	+$5.08K	0.82%	35
2021 Q4	$1.08M	Buy	+7,966	New	+$941K	0.96%	29

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

NCM Capital Management's ABBV Position: Q2 2026 in Review

NCM Capital Management increased its AbbVie (ABBV) stake by 3.3% in Q2 2026, buying an estimated $53.8K and bringing the position to 7,769 shares worth $1.96M. The position accounts for 0.6% of the portfolio, ranked #44.

NCM Capital Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

NCM Capital Management held 7,769 shares of AbbVie worth $1.96M as of Q2 2026.
NCM Capital Management bought 250 AbbVie shares in Q2 2026, an estimated $53.8K.
AbbVie made up 0.6% of NCM Capital Management's portfolio in Q2 2026, its #44 holding.
NCM Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on NCM Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.